These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 27726412)

  • 1. Predicting Glioblastoma Recurrence by Early Changes in the Apparent Diffusion Coefficient Value and Signal Intensity on FLAIR Images.
    Chang PD; Chow DS; Yang PH; Filippi CG; Lignelli A
    AJR Am J Roentgenol; 2017 Jan; 208(1):57-65. PubMed ID: 27726412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonenhancing peritumoral hyperintense lesion on diffusion-weighted imaging in glioblastoma: a novel diagnostic and specific prognostic indicator.
    Kolakshyapati M; Adhikari RB; Karlowee V; Takayasu T; Nosaka R; Amatya VJ; Takeshima Y; Akiyama Y; Sugiyama K; Kurisu K; Yamasaki F
    J Neurosurg; 2018 Mar; 128(3):667-678. PubMed ID: 28362236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.
    Doskaliyev A; Yamasaki F; Ohtaki M; Kajiwara Y; Takeshima Y; Watanabe Y; Takayasu T; Amatya VJ; Akiyama Y; Sugiyama K; Kurisu K
    Eur J Radiol; 2012 Feb; 81(2):339-44. PubMed ID: 21129872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of recurrent glioblastoma after laser interstitial thermal therapy: The role of diffusion imaging.
    Mahammedi A; Bachir S; Escott EJ; Barnett GH; Mohammadi AM; Larvie M
    Neurooncol Adv; 2019; 1(1):vdz021. PubMed ID: 32642657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
    Auer TA; Breit HC; Marini F; Renovanz M; Ringel F; Sommer CJ; Brockmann MA; Tanyildizi Y
    J Neuroradiol; 2019 Feb; 46(1):36-43. PubMed ID: 29733920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
    Khalifa J; Tensaouti F; Lotterie JA; Catalaa I; Chaltiel L; Benouaich-Amiel A; Gomez-Roca C; Noël G; Truc G; Péran P; Berry I; Sunyach MP; Charissoux M; Johnson C; Cohen-Jonathan Moyal E; Laprie A
    J Neurooncol; 2016 Oct; 130(1):181-192. PubMed ID: 27502603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.
    Elson A; Paulson E; Bovi J; Siker M; Schultz C; Laviolette PS
    J Neurooncol; 2015 May; 123(1):179-88. PubMed ID: 25894597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infiltrative patterns of glioblastoma: Identification of tumor progress using apparent diffusion coefficient histograms.
    Lutz K; Wiestler B; Graf M; Bäumer P; Floca R; Schlemmer HP; Heiland S; Wick W; Bendszus M; Radbruch A
    J Magn Reson Imaging; 2014 May; 39(5):1096-103. PubMed ID: 24115401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurements of diagnostic examination performance using quantitative apparent diffusion coefficient and proton MR spectroscopic imaging in the preoperative evaluation of tumor grade in cerebral gliomas.
    Server A; Kulle B; Gadmar ØB; Josefsen R; Kumar T; Nakstad PH
    Eur J Radiol; 2011 Nov; 80(2):462-70. PubMed ID: 20708868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating Glioblastoma from Primary Central Nervous System Lymphoma: The Value of Shaping and Nonenhancing Peritumoral Hyperintense Gyral Lesion on FLAIR Imaging.
    Wang P; Shi YH; Li JY; Zhang CZ
    World Neurosurg; 2021 May; 149():e696-e704. PubMed ID: 33548537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of peritumoral minimum apparent diffusion coefficient for differentiation of glioblastoma multiforme from solitary metastatic lesions.
    Lee EJ; terBrugge K; Mikulis D; Choi DS; Bae JM; Lee SK; Moon SY
    AJR Am J Roentgenol; 2011 Jan; 196(1):71-6. PubMed ID: 21178049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying Voxels at Risk for Progression in Glioblastoma Based on Dosimetry, Physiologic and Metabolic MRI.
    Anwar M; Molinaro AM; Morin O; Chang SM; Haas-Kogan DA; Nelson SJ; Lupo JM
    Radiat Res; 2017 Sep; 188(3):303-313. PubMed ID: 28723274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Mischel PS; Nghiemphu PL; Lalezari S; Schmainda KM; Pope WB
    Neuro Oncol; 2011 Oct; 13(10):1151-61. PubMed ID: 21856685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiforme.
    Paldino MJ; Barboriak D; Desjardins A; Friedman HS; Vredenburgh JJ
    J Magn Reson Imaging; 2009 May; 29(5):1199-205. PubMed ID: 19388113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Nghiemphu PL; Pope WB
    Magn Reson Med; 2012 Jan; 67(1):237-45. PubMed ID: 21702063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.
    Zolal A; Juratli TA; Linn J; Podlesek D; Sitoci Ficici KH; Kitzler HH; Schackert G; Sobottka SB; Rieger B; Krex D
    J Neurooncol; 2016 May; 127(3):551-7. PubMed ID: 26830088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multiparametric Model for Mapping Cellularity in Glioblastoma Using Radiographically Localized Biopsies.
    Chang PD; Malone HR; Bowden SG; Chow DS; Gill BJA; Ung TH; Samanamud J; Englander ZK; Sonabend AM; Sheth SA; McKhann GM; Sisti MB; Schwartz LH; Lignelli A; Grinband J; Bruce JN; Canoll P
    AJNR Am J Neuroradiol; 2017 May; 38(5):890-898. PubMed ID: 28255030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increase in FLAIR Signal of the Fluid Within the Resection Cavity as Early Recurrence Marker: Also Valid for Brain Metastases?
    Bette S; Gempt J; Wiestler B; Huber T; Specht H; Meyer B; Zimmer C; Kirschke JS; Boeckh-Behrens T
    Rofo; 2017 Jan; 189(1):63-70. PubMed ID: 28002859
    [No Abstract]   [Full Text] [Related]  

  • 20. Utility of tubular retractors to minimize surgical brain injury in the removal of deep intraparenchymal lesions: a quantitative analysis of FLAIR hyperintensity and apparent diffusion coefficient maps.
    Bander ED; Jones SH; Kovanlikaya I; Schwartz TH
    J Neurosurg; 2016 Apr; 124(4):1053-60. PubMed ID: 26430838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.